NanoNewron
- Biotech or pharma, therapeutic R&D
NanoNewron, a NJ based spin-off of Rutgers University, is developing a new approach to treat Alzheimer’s Disease by carrying biologics across the blood-brain barrier with its NewroBus technology. NanoNewron developed innovative nano-size, single-chain antibodies, the “NewroBus", that can carry biologics efficiently and safely through the BBB by exploiting Transferrin Receptor 1 (TfR1) mediated transcytosis.
There is growing evidence that the inflammatory cytokine TNF-α plays a central role in the pathophysiology of Alzheimer’s Disease. Potent TNF-α inhibitors, developed in house, have been linked to a NewroBus molecule, creating a compound that crosses the BBB delivering the TNF-α inhibitors inside the brain and achieving high inhibition of the inflammatory cytokine TNF-α. We are starting IND enabling studies, plannign to file an IND next year,
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}